MR-Guided Ultrasound Delivers Antibody Therapy to Brain Tumours

MR-Guided Ultrasound Delivers Antibody Therapy to Brain Tumours
share Share

Canadian researchers at Sunnybrook Health Sciences Centre, safely delivered trastuzumab antibody therapy to breast cancer brain metastases using magnetic resonance (MR)-guided focused ultrasound. This study provides the first visual confirmation that focused ultrasound can improve the delivery of targeted antibody therapy across the blood-brain barrier (BBB). 


The team used MR to guide a focused ultrasound device, Insightec's Exablate Neuro, to open the BBB and allow intravenous trastuzumab to effectively reach Her2-positive brain tumours. The BBB presents a challenge for developing central nervous system (CNS) therapeutics because it transforms the CNS into an immunologically and pharmacologically privileged compartment. Antibodies do not normally cross the BBB, so treating Her2-positive brain tumours with trastuzumab is problematic, unless there the BBB can be made permeable. Furthermore, surgical or radiation options for brain tumours are highly invasive if available. The research team’s method of inducing BBB permeability has the advantage of being localised, temporary, and non-invasive.


Trastuzumab delivery into the tumour sites was confirmed using 111In-BzDTPA-NLS-trastuzumab SPECT imaging. Four patients with Her2-positive breast cancer brain metastases were enrolled in a clinical trial, phase 1, single-arm open-labelled study. Patients received 20 treatments consisting of MR-guided focused ultrasound along with intravenous trastuzumab-based therapies. No treatment-related serious adverse events occurred. With treatment, tumour measurements decreased by 19 ± 12%.

This study shows the promise of this approach for CNS drug delivery. The technology can be applied to many CNS diseases where efficacious drugs for other organ compartments exist but cannot be used in the CNS because of poor BBB permeability.

«« Deep Learning with Whole-body MRI Recognises Diabetes

FDA Approves Delphinus 3D Whole Breast Ultrasound System »»


Meng, Y., et al. (2021) MR-guided focused ultrasound enhances delivery of Trastuzumab to Her2-positive brain metastases. Science Translational Medicine.

Published on : Mon, 25 Oct 2021

Related Articles
Disruptive Tech: Low-Cost Low-Field MRIs

During magnetic resonance imaging (MRI) technology’s dawn years, the cost vs the performance gains associated with stronger magnetic... Read more

During RSNA 2021 on 29 November 2021, RSNA recognised the winners of a two-part brain tumour AI challenge at Chicago’s McCormick... Read more

Patient Satisfaction Drives Imaging Volumes for Outpatient MRI Clinics

A study recently published in Current Problems in Diagnostic Radiology found that outpatient imaging volumes increase in MRI... Read more

MRI, Ultrasound, breast cancer, brain tumour, antibody therapy Toronto researchers use MR-guided focused ultrasound to deliver the antibody therapy, Trastuzumab, to Her2-positive brain metastases.

No comment

Please login to leave a comment...

Highlighted Products